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ABSTRACT 
Glucocorticoids (GCs) regulate skin homeostasis and combat cutaneous inflammatory 
diseases, however, adverse effects of chronic GC treatments limit their therapeutic use. 
GCs bind and activate the GC receptor (GR) and the mineralocorticoid receptor (MR), 
transcription factors that recognize identical hormone responsive elements (HREs). 
Whether epidermal MR mediates beneficial or deleterious GC effects is of great interest 
for improving GC-based skin therapies. MR epidermal knock-out (MREKO) mice 
exhibited increased keratinocyte proliferation and differentiation and showed resistance 
to GC-induced epidermal thinning. However, crucially, loss of epidermal MR rendered 
mice more sensitive to inflammatory stimuli and skin damage. MREKO mice showed 
increased susceptibility to PMA-induced inflammation with higher cytokine induction. 
Likewise, cultured MREKO keratinocytes had increased PMA-induced NF-B activation, 
highlighting an anti-inflammatory function for MR. GC-induced transcription was 
reduced in MREKO keratinocytes, at least partially due to decreased recruitment of GR to 
HRE-containing sequences. Our results support a role for epidermal MR in adult skin 
homeostasis and demonstrate non-redundant roles for MR and GR in mediating GC 
actions. 
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INTRODUCTION 
The mineralocorticoid receptor (MR) and glucocorticoid (GC) receptor (GR) are 
structurally and functionally related proteins that belong to the steroid receptor 
superfamily and act as ligand-activated transcription factors (TFs) recognizing the same 
hormone responsive elements (HREs) on target genes (Viengchareun et al., 2007; 
Odermatt and Atanasov, 2009; Oakley and Cidlowski, 2013; Vandevyver et al., 2013). 
In fact, although many GC-target genes are regulated by both MR and GR in different 
cell types, the exact contribution of each receptor is largely unknown (Oakley and 
Cidlowski, 2015). 
MR can bind its physiological ligand aldosterone but also GCs (cortisol in 
humans and corticosterone in rodents) with similar affinity. Indeed, MR binds GCs with 
a 10-fold higher affinity than GR itself. Given that GC plasma concentration exceeds 
that of aldosterone by approximately 100-fold, all MR should be theoretically occupied 
by GCs (Funder, 2010; Gomez-Sanchez and Gomez-Sanchez, 2014). However, MR 
occupancy by GCs is limited by their interconversion between inactive and active 
forms, which is modulated by the enzymes 11b-hydroxysteroid dehydrogenase type 1 
and 2. Therefore, the formation of different receptor/ligand complexes in a given cell 
type will be determined by the relative expression and function of MR, GR, aldosterone 
and GCs (Oakley and Cidlowski, 2015). 
MR and aldosterone play vital roles in renal sodium and water reabsorption, as 
MR-/- mice die postnatally from severe dehydration (Berger et al., 1998). However, it is 
currently recognized that MR exerts a broader range of functions in non-classic target 
tissues (Martinerie et al., 2013; Jaisser and Farman, 2016). In fact, MR activation is 
involved in numerous pathophysiological effects including inflammation, hypertrophy, 
and fibrosis, in tissues including the renal, adipose, and cardiovascular system (Brown, 
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2013). These findings are consistent with clinical studies demonstrating that besides the 
classical use of MR antagonists for treating hypertension, pharmacological blockade of 
MR was also beneficial for patients suffering from other inflammatory and fibrotic 
diseases (Jaisser and Farman, 2016). The mechanisms mediating pathological MR 
activation include activation of the NF-B pathway and oxidative stress as well as up-
regulation of MR-targets including pro-fibrotic genes (Bauersachs et al., 2015). 
However, MR activation can be beneficial in certain circumstances by improving 
capillary density and combating inflammation through inhibition of NF-B activity 
(Messaoudi et al., 2009; Bergman et al., 2010). 
The use of GCs is widely prescribed for treating cutaneous diseases due to their 
anti-inflammatory and anti-proliferative effects. However, adverse effects caused by 
chronic GC treatments such as skin atrophy and delayed wound healing limit their 
therapeutic use (Schäcke et al., 2002; Cato et al., 2004; Pérez, 2011). While the crucial 
function of GR in skin pathophysiology has been widely characterized, the exact role of 
MR in this tissue deserves further study (Farman et al., 2010; Pérez, 2011; Farman and 
Nguyen, 2015). 
MR is expressed in epidermal keratinocytes, hair follicles, sebaceous and sweat 
glands in humans and mice (Kenouch et al., 1994; Sainte-Marie et al., 2007; Mitts et al., 
2010). We previously reported that MR reached a peak of expression at the mRNA and 
protein level in late developing embryonic skin where stratification occurs (Boix et al., 
2015). After birth, MR mRNA expression was drastically reduced (more than 10-fold in 
adult skin), and MR protein was not detectable using currently available antibodies. MR 
inactivation caused minor defects in early stages of mouse skin development; however, 
consequences in the adulthood could not be addressed due to the perinatal death of MR-
/- mice (Boix et al., 2015). 
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 In vitro studies with MR antagonists, agonists and/or its physiological ligand 
aldosterone have provided important clues about its function in skin. For instance, skin 
aging was related to up-regulation of MR since its pharmacological blockade 
suppressed inflammation and age-related changes in a mouse model of metabolic 
syndrome (Nagase et al., 2013). One caveat is that these studies cannot exclude that the 
compounds used act through other receptors besides MR (Gomez-Sanchez, 2016). For 
example, the MR antagonist spironolactone can exert certain effects independently of 
MR likely through RXR in colon carcinoma cells (Leung et al., 2013). In addition, the 
physiological MR ligand aldosterone showed receptor-dependent and independent 
actions in the deposition of dermal collagen and elastin, respectively, in human skin 
explants (Mitts et al., 2010). Overall, these evidences highlight the necessity for tissue-
specific loss-of-function models to elucidate the precise role of MR in skin 
physiopathology. 
Mice with keratinocyte-specific overexpression of either MR or GR exhibited 
strong similarities in their skin phenotypes, including atrophic skin, reduced hair follicle 
number and impaired epidermal maturation (Pérez et al., 2001; Cascallana et al., 2005; 
Sainte-Marie et al., 2007). This, along with the functional homology between MR and 
GR raised the question of whether some of the GC effects might be mediated by MR 
(Farman et al., 2010; Pérez, 2011; Farman and Nguyen, 2015). Very recently, Farman´s 
group demonstrated that topical application of a pharmacological MR antagonist 
partially reversed the GC-induced skin atrophy in human healthy skin (Maubec et al., 
2015). 
Here we report the generation of epidermal-specific MR knock-out mice 
(MREKO) and address the role of this TF in skin pathophysiology. We demonstrate that 
keratinocyte MR contributed to GC-induced epidermal thinning but not reduced 
 6
collagen deposition while it was required for normal keratinocyte migration. 
Mechanistically, the transcriptional response to GCs through consensus HREs involved 
both MR and GR. In contrast to the MR pro-inflammatory role in other tissues, 
epidermal MR exerted anti-inflammatory actions, similar to GR, which were mediated 
at least partially, through repression of NF-B activity. Altogether, our results 
demonstrate complex roles for epidermal MR in adult skin homeostasis and disease, 
with non-redundant roles for MR and GR in mediating GC-dependent transcription. 
 
 
RESULTS AND DISCUSSION 
Epidermal MR plays a role in adult skin homeostasis 
We have generated mice with MR inactivation restricted to epidermal keratinocytes 
(MR epidermal knock-out or MREKO mice; Fig. 1a-c). Adult MREKO mice were viable 
and fertile and showed minor skin defects including statistically significant increases in 
epidermal thickness as well as abnormal K6 staining, which correlated with increased 
keratinocyte proliferation (Fig. 1d-f). Consistently, we also detected accelerated growth 
in MREKO relative to control (CO) cultured keratinocytes (Fig. 1g). 
The epidermis of MREKO mice showed focally augmented keratinization (Fig. 
1d, arrows) and, consistently, MREKO keratinocytes showed constitutively increased 
mRNA levels of the differentiation markers Small proline rich repeat (Sprr)2d and 
Defensin beta1 (Defb1) relative to CO (Fig. 1i). When keratinocytes were induced to 
differentiate with high-calcium concentrations, there were more corneocytes and up-
regulation of Sprr2d and Defb1 genes was augmented in MREKO relative to CO cells 
(Fig. 1h, i; Hennings et al., 1980). 
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In CO cells, the expression of MR (Nr3c2) mRNA decreased around 40% upon 
calcium-induced differentiation while that of GR (Nr3c1) showed an increased trend 
(not statistically significant) indicating that these two receptors play contrasting roles 
during this process (Fig. 1i). This is consistent with the reduced up-regulation of Sprr2d 
and Defb1 detected in calcium-treated GR-deficient cells (Sevilla et al., 2015). The fact 
that GR expression did not change in undifferentiated MREKO vs CO cells suggested that 
the observed morphological and gene expression changes are due to the lack of MR and 
not to changes in GR expression (Fig. 1h, i). These findings were confirmed in vivo, 
since GR mRNA levels were also unchanged in untreated MREKO relative to CO mouse 
skin (Fig. S1a-c).  
 
MR protects against skin damage 
We evaluated whether epidermal MR inactivation had an impact in local damage caused 
by repetitive application of the irritant SDS. In CO mice, SDS induced epidermal 
thickening, K6 expression, and hyperkeratosis after 5 d of treatment (Fig. 2a). 
Importantly, MREKO mice showed overall augmented epithelial damage upon SDS 
treatment as shown by histopathological analysis as well as increased epidermal 
thickness and keratinocyte proliferation (Fig. 2a-c). Our data indicate that epidermal 
MR inactivation results in increased proliferation both in basal and pathological 
conditions. 
We assessed the expression of the calcium-binding protein S100A9, up-
regulated in various skin inflammatory conditions including psoriasis (Kerkhoff et al., 
2012), and found significant up-regulation in SDS-treated MREKO relative to CO mice 
(Fig. 2d; 6-fold increase). Since STAT3 is involved in controlling S100A9 expression 
upon diseased conditions, we also assessed the expression of total and phosphorylated 
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(p)-STAT3. Our data demonstrate four-fold increases of both constitutive and SDS-
induced STAT3 activity in MREKO vs CO mice (Fig. 2 e). Remarkably, the increased 
susceptibility to epidermal damage of MREKO mice highly resembled the response of 
GREKO mice (Sevilla et al., 2013) indicating that both MR and GR play non-redundant 
protective roles in skin. Since SDS down-regulated GR mRNA levels similarly in CO 
and MREKO mice (Fig. S1a, approximately 50%), our results indicate that the more 
exaggerated response in SDS-treated MREKO mice is due to the lack of epidermal MR 
and not to changes in GR expression. 
 
MR plays an anti-inflammatory role in skin through NF-B inhibition 
The response to PMA-induced ear edema was significantly higher in MREKO relative to 
CO mice, correlating with the presence of inflammatory abscesses (Fig. 3a, asterisk; b). 
Consistently, after PMA treatment, we detected significant increases of the pro-
inflammatory cytokines Il6 and Slpi in MREKO relative to CO mice; however, Tnf 
expression was unchanged (Fig. 3c). Note that PMA treatment did not significantly 
change GR expression in MREKO or CO skin (Fig. S1b), suggesting that its effects are 
directly related to epidermal MR absence. We also assessed cytokine expression in 
cultured keratinocytes and detected significant increases in TnfIl6 and Slpi in vehicle 
and PMA-treated MREKO versus CO cells (Fig. 3d). The fact that the PMA-induced 
cytokine expression observed in MREKO skin was recapitulated in cultured keratinocytes 
demonstrates that the anti-inflammatory function of MR is keratinocyte-specific. 
Given the crucial role of NF-B in skin inflammation, we assessed its activation 
upon PMA treatment in CO and MREKO cultured keratinocytes by measuring the 
activity of a B-luciferase reporter construct (Fig. 3e). For comparative purposes, and 
given the well-known anti-inflammatory function of GR in keratinocytes (Busillo and 
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Cidlowski, 2013; Sevilla et al., 2013), we also used epidermal GR knock-out cells 
(GREKO, Latorre et al., 2013). The B-luciferase activity was four-fold higher in MR-
deficient cells relative to CO, and similar to that observed in GR-deficient keratinocytes 
(Fig. 3e). Remarkably, our findings indicate that both nuclear receptors play anti-
inflammatory roles in keratinocytes and that one cannot compensate for the other’s 
absence.  
 
Normal cutaneous wound healing requires MR 
The importance of correct regulation of GC levels in skin wound repair is well known 
as chronic GC treatments delay this process (Beer et al., 2000; Stojadinovic et al., 2005; 
Pastar et al., 2014). It is also widely recognized that epidermal keratinocytes are able to 
synthesize GCs in response to wounding; consistently, local blockade of GC production 
using inhibitors of 11b-hydroxysteroid dehydrogenase type 1 accelerated wound healing 
(Vukelic et al., 2011; Tiganescu et al., 2013; Youm et al., 2013, Slominsky et al., 2014). 
Keratinocytes play a major role in the healing response by proliferating and 
migrating into the wound (re-epithelialization), thus restoring the epidermis after injury 
(Pastar et al., 2014). We examined the healing response in MREKO and CO mice by 
performing full-thickness dorsal wounds. Quantitation of wound closure showed no 
statistically significant variation among genotypes (Fig. 4a). The percentage of re-
epithelialization at d 7 was also similar in MREKO relative to CO despite increased 
keratinocyte proliferation (Fig. 4b, c). This may be due to defective keratinocyte 
migration in MREKO wounds, which exhibited unorganized structure and abnormal K6 
localization (Fig. 4d). In addition, quantitation analysis of 7d trichromic stained wounds 
demonstrated statistically significant reduction of collagen deposition (around 45%) in 
MREKO vs CO (Fig. 4d, e). Note that no statistically significant differences were found 
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in untreated MREKO relative to CO mice (Fig. S2), suggesting that MR mainly 
contributes to these differences only in pathological conditions. 
Wound scratch experiments demonstrated retarded cell migration of MREKO 
keratinocytes at all time points examined (Fig. 4f, g). Moreover, treatment of CO 
keratinocytes with the MR pharmacological antagonist eplerenone also elicited 
significant delays in keratinocyte migration at 8-30h post-wounding (Fig. S3), further 
confirming that these effects are due to MR inactivation and not related to differences 
between cell lines. Overall, our results demonstrate that epidermal inactivation of MR 
does not improve wound healing but rather results in alterations in keratinocyte 
migration and reduced dermal remodeling. 
 
Epidermal MR inactivation partially protects against GC-induced skin atrophy 
We assessed whether skin atrophy caused by continuous GC treatments might be 
mediated by epidermal MR. CO mice topically treated with the GC analog 
dexamethasone (Dex) showed epidermal thinning, decreased keratinocyte proliferation, 
reduced expression of K5, and repression of Cyclin d1 (Ccnd1) (Fig. 5a, c, d). In 
contrast, in MREKO mice, Dex inhibition of keratinocyte proliferation was partially 
reversed and there was no repression of Ccnd1. It has been widely reported that both 
Krt5 and Ccnd1 are target genes negatively regulated by GR, partly accounting for GC 
anti-proliferative actions in several cell types including keratinocytes (Radoja et al., 
2000). Since GR expression did not change in Dex-treated MREKO or CO mouse skin 
(Fig. S1c), our findings indicate that MR also participates in gene repression and that 
GR is not sufficient to mediate this process. Our data are in agreement with a recent 
report demonstrating that combined treatments using GCs plus a pharmacological MR 
antagonist partially reversed the GC-induced epidermal atrophy (Maubec et al., 2015). 
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We next assessed the expression of Col1a1 in basal conditions and found 
significant increases in MREKO relative to CO skin (Fig. 5e). However, Dex treatments 
reduced Col1a1 mRNA to similar levels in both genotypes (Fig. 5e). Since other reports 
described that MR contributes to collagen deposition in dermal fibroblasts (Mitts et al., 
2010) it is possible that the atrophogenic effects of Dex are also due to MR activation in 
other cell types besides keratinocytes. Thus, contrary to other tissues in which MR 
blockade is beneficial to combat fibrosis (e.g., renal and cardiovascular pathologies), 
epidermal MR inactivation does not have an impact on cutaneous fibrosis (Fig. S2 and 
5e). Although MR inactivation in skin can be beneficial by partially counteracting GC-
associated undesired effects, our findings highlight that it can also have adverse 
consequences in this tissue in response to stressors. Therefore, prior to the use of MR 
antagonists the distinct cell-type specific functions of this nuclear receptor must be 
taken into account (Gomez-Sanchez, 2016).  
 
MR is required for transcriptional up-regulation of GC-target genes in 
keratinocytes 
We next analyzed whether keratinocyte MR inactivation had an impact on Dex-induced 
transcriptional responses by measuring the activity of a GRE-luciferase reporter in 
MREKO and CO keratinocytes. In CO cells, Dex treatment induced an increase of GRE-
luciferase activity of approximately 8-fold, which was decreased in MREKO cells by 
around 40% (Fig. 6a). Further supporting the functional role of MR in mediating GC 
transcriptional responses in keratinocytes, Dex-induction of GRE-luciferase activity in 
CO cells was significantly decreased in the presence of eplerenone by approximately 
50% (Fig. S4). 
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Transfection of increasing amounts of HA-MR in MREKO cells restored the 
transcriptional response to baseline levels (Fig. 6a, b). It must be noted that Dex 
effectively induced both MR and GR nuclear translocation in HA-MR transfected cells 
as shown by immunofluorescence (Fig. 6c, see merge). Importantly, the total and 
phosphorylated levels of GR were similar in MREKO relative to CO cells (Fig. 6b, d) 
indicating that there was no functional compensation by GR. 
To understand how MR loss impairs GC-transcriptional responses in 
keratinocytes, we focused on Tsc22d3/Gilz, a classic target gene of both MR and GR 
that is induced by Dex in many cell types (Ronchetti et al., 2015). In keratinocytes, we 
previously demonstrated that Dex up-regulates Gilz by inducing GR recruitment to 
HRE-containing regulatory sequences (Sevilla et al., 2015). Consistent with the reduced 
transactivation of GRE-luciferase assays, Dex induction of Gilz mRNA levels was 
significantly reduced in MREKO vs CO keratinocytes (Fig. 6e; 1.8-fold vs 5-fold). 
Analogous to MR-deficient keratinocytes, GREKO cells were unable to induce Gilz 
mRNA levels in response to Dex (Fig. 6e).  
We then assessed GR recruitment to Gilz regulatory sequences after Dex 
treatment in MREKO and CO cells by chromatin immunoprecipitation (ChIP)-QPCR 
assays and detected a significant decrease of GR binding in MREKO keratinocytes (Fig. 
6f). This together with the fact that MR reinsertion into MREKO keratinocytes restored 
GC-mediated transactivation demonstrates that MR is necessary for optimal GC 
transcriptional regulation. To dissect further the relative contribution of MR and GR in 
GC-transactivation, we used GREKO keratinocytes. Upon HA-MR transfection, Dex 
increased GRE-luciferase activity about 40-fold (Fig. 6g, h), demonstrating that MR is 
transcriptionally functional even in the absence of GR. However, GR transfection in 
GREKO cells increased GRE-luciferase activity to a much higher extent (around one 
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order of magnitude) than MR, and co-transfection of both receptors did not produce an 
additive effect (Fig. 6g, h). Overall, our results indicate that both MR and GR are 
required to modulate transcriptional regulation in response to GCs.  
Altogether, our findings support complex roles for epidermal MR in healthy and 
diseased skin. Epidermal MR inactivation disturbed skin homeostasis increasing the 
sensitivity to barrier disruption and inflammation. The observed increased activation of 
pro-inflammatory TFs such as STAT3 and NF-B highlights an anti-inflammatory 
function for MR in keratinocytes. In addition to its protective roles, epidermal MR 
partially mediated GC-induced epidermal thinning. Our in vitro studies also 
demonstrated that MR inactivation in keratinocytes significantly impaired GC-
dependent transactivation at least partly due to reduced GR recruitment to HRE-
containing target genes. Overall, our data support common and distinct roles for MR 
and GR in skin, which must be taken into account for the design of GC-based skin 
therapies. 
 
 
MATERIALS AND METHODS 
 
Animal experimentation and treatments 
Animal experimentation was conducted according to current Spanish and European 
regulations and approved by our institution’s ethics committee (SAF2011-28115 and 
SAF2014-59474-R). MRloxP/loxP and K5-Cre mice have been reported (Berger et al., 
2006; Ramírez et al., 2004). Intercrosses of these mice led to the double transgenic K5-
cre+/-//MRloxP/loxP or MREKO; 0Cre//MRloxP/loxP mouse littermates were used as controls. 
Genotyping was performed using primers in Table 1. 
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Topical treatments included Dex (8g/200l; for 48h or for 7d every 48h; 
Sigma Chemical Co., St. Louis, MO), and SDS (10%/100l daily for 5d; Merck, 
Darmstadt, Germany). PMA (8g/50l; Sigma) was applied to both sides of mouse 
ears 48h prior to sacrifice. To assess cellular proliferation, mice were injected with 
BrdU 1 h prior to sacrifice (130 g/g of body weight, Sigma). 
 For cutaneous wounding assays, full-thickness wounds (n=4 wound per mouse) 
were performed (6 mm, Biopsy punch, Stiefel, Brentford, UK) in female MREKO and 
CO littermates (n= at least 7 mice per genotype), and wound areas were recorded daily, 
as described (Sanchis et al., 2012). Mice were sacrificed 7 d post-wounding. 
 
Histological analysis 
Dorsal skin or ear samples were collected, fixed in 70% ethanol and paraffin-embedded 
for histopathological analysis (Sevilla et al., 2013). See supplementary information for 
quantitation analyses. 
 
Immunoblotting and Antibodies 
Immunoblotting was performed as described (Sevilla et al., 2013). Mouse monoclonal 
antibodies used were specific for HA (HA-11, Biolegend, San Diego, CA), and tubulin 
(T6199, Sigma). Rabbit polyclonal antibodies used were specific for GR (sc-1004, 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA), actin (A-2066, Sigma), p-GR 
(Ser211; #4161), STAT3 (#9132), and p-STAT3 (Tyr705 D3A7; #9145) (Cell 
Signaling Technology Inc., Beverley, MA). Goat anti-S100A9 was from R&D Systems, 
Minneapolis, MN. Secondary peroxidase-conjugated anti-rabbit (NA934) and anti-
mouse (NA931) antibodies were from GE Healthcare.  
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 Rabbit polyclonal antibodies against K5 (PRB-160P), K6 (PRB-169P), and 
loricrin (PRB-145P) (Biolegend), and mouse anti-BrdU (Clone BMC 9318, Roche 
Diagnostics, Mannheim, Germany) were used. Secondary biotin-conjugated anti-rabbit 
or anti-mouse antibodies (Jackson ImmunoResearch) and secondary Alexa Fluor® anti-
rabbit (555, A-31572) or anti-mouse (488, A-21202) antibodies were used (Thermo 
Fisher). 
 
Cell culture 
See supplementary information for details of generation and maintenance of cell lines. 
Cultured keratinocytes were grown overnight in medium containing charcoal-stripped 
serum prior to Dex treatment, to deplete steroid hormones, then treated with Dex (100 
nM), PMA (100nM), or eplerenone (Sigma, 10 µM) at the indicated times. To induce 
terminal differentiation, keratinocytes were incubated with medium containing 1.2 mM 
CaCl2 for 72h. 
 
RNA isolation, Quantitative RT-PCR, and Chromatin immunoprecipitation (ChIP) 
RNA isolated from mouse dorsal skin, ear or cultured keratinocytes using Trizol 
(Thermo Fisher) was used to generate cDNA using RevertAid H Minus Reverse 
Transcriptase (Thermo Fisher) for qPCR that was performed as described using specific 
oligonucleotides (Sevilla et al. 2015; Table S1). 
ChIP experiments were performed using adult keratinocyte cell lines as 
described (Sevilla et al., 2015). The QPCR was performed to determine the relative 
amplification of specified genomic sites in Dex vs mock-treated ChIPs, which were 
normalized to the amplification values of respective inputs (primers Table S1). 
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Statistics 
Experimental data were analyzed using Microsoft Excel and IBM SPSS Statistics 23 
software. In all graphs, unless otherwise mentioned, mean values ± SD are shown. 
When statistical analysis was performed with relative values, data were first subjected 
to logarithmic transformation. Prior to parametric testing, the Levene’s test was used to 
determine whether samples within groups had equal variance. For comparisons between 
two experimental groups, we used the Student’s unpaired two-tailed t-test. For 
comparisons among more than two experimental groups, we used the one-way ANOVA 
which if statistically significant was followed by a post hoc Tukey multiple comparison 
test. P values less than 0.05 were considered statistically significant. 
 
CONFLICT OF INTEREST 
The authors declare that they have no conflict of interest. 
 
ACKNOWLEDGEMENTS 
This work was supported by grant SAF2011-28115 and SAF2014-59474-R (MINECO, 
Spanish Government). JB and EC are recipients of FPI (BES-2012-0578) and FPU 
(AP201-06094) fellowships of MINECO, respectively. We thank COST ADMIRE BM-
1301 and NURCAMEIN (SAF2015-71878-REDT) for support for dissemination. We 
are grateful to Prof. JL. Jorcano and A. Ramírez for providing us with K5-cre mice, 
Prof. G. Schütz and Jan Tuckermann for providing us with MRloxP/loxP mice, D. Álvarez 
de la Rosa for pCDNA4-HA-MR, and JM. Torres for NF5x-Luciferase constructs. 
We specially thank Jose Nieto for his expert technical help with mice and histological 
work, and V. Marcos-Garcés for morphometrical analysis of adult mouse skin. 
 
 17
REFERENCES 
 
Aguilar-Sánchez C, Hernández-Díaz I, Lorenzo-Díaz F, Navarro JF, Hughes 
TE, Giraldez T et al. Identification of permissive insertion sites for generating 
functional fluorescent mineralocorticoid receptors. Endocrinology 2012;153:3517–25. 
 
Allgood VE, Oakley RH, Cidlowski JA. Modulation by vitamin B6 of glucocorticoid 
receptor-mediated gene expression requires transcription factors in addition to the 
glucocorticoid receptor. J Biol Chem 1993;268:20870–76. 
 
Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and 
mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. 
Hypertension 2015;65:257–263. 
 
Beer HD, Fässler R, Werner S. Glucocorticoid-regulated gene expression during 
cutaneous wound repair. Vitam Horm 2000;59:217–39. 
 
Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H et al. Mineralocorticoid 
receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci 
USA 1998;95:9424–29. 
 
Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM et al. Loss of 
the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci 
USA 2006;103:195–200. 
 
Bergmann A, Eulenberg C, Wellner M, Rolle S, Luft F, Kettritz R. Aldosterone 
abrogates nuclear factor kappaB-mediated tumor necrosis factor alpha production in 
human neutrophils via the mineralocorticoid receptor. Hypertension 2010;55:370–79. 
 
Boix J, Carceller E, Sevilla LM, Marcos-Garcés V, Pérez P. The mineralocorticoid 
receptor plays a transient role in mouse skin development. Exp Dermatol 2015;25:69–
71. 
 
Brown N. Contribution of aldosterone to cardiovascular and renal inflammation and 
fibrosis Nat Rev Nephrol 2013;9:459–69. 
 
Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: 
ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab 2013;24:109–
19. 
 
Cato AC, Schäcke H, Sterry W, Asadullah K. The glucocorticoid receptor as target for 
classic and novel anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy 
2004;3:347–55. 
 
Cascallana JL, Bravo A, Donet E, Leis H, Lara MF, Paramio JM et al. Ectoderm-
targeted overexpression of the glucocorticoid receptor induces hypohidrotic ectodermal 
dysplasia. Endocrinology 2005;146:2629–38. 
 
 18
Farman N, Maubec E, Poeggeler B, Klatte JE, Jaisser F, Paus R. The mineralocorticoid 
receptor as a novel player in skin biology: beyond the renal horizon? Exp Dermatol 
2010;19:100–07. 
 
Farman N, Nguyen VT. A novel actor in skin biology: the mineralocorticoid receptor. 
Exp Dermatol 2015;25:24–5. 
 
Funder JW. Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, 
and Future. Endocrinology 2010;151:5098–5102. 
 
Gomez-Sanchez E, Gomez-Sanchez CE.The multifaceted mineralocorticoid receptor. 
Compr Physiol 2014;4:965–94. 
 
Gomez-Sanchez EP. Third-generation Mineralocorticoid Receptor Antagonists: Why 
Do We Need a Fourth? J Cardiovasc Pharmacol 2016;67:26–38. 
 
Hennings H, Michael D, Cheng C, Steinert P, Holbrook K, Yuspa SH. Calcium 
regulation of growth and differentiation of mouse epidermal cells in culture. Cell 
1980;19:245–54. 
 
Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: 
Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev 2016;68:49–75. 
 
Kenouch S, Lombes M, Delahaye F, Eugene E, Bonvalet JP, Farman N. Human skin as 
target for aldosterone: coexpression of mineralocorticoid receptors and 11 beta-
hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 1994;79:1334–41.  
 
Kerkhoff C, Voss A, Scholzen TE, Averill MM, Zänker KS, Bornfeldt KE. 
Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol 2012;21:822–
26. 
 
Latorre V, Sevilla LM, Sanchis A, Pérez P. Selective ablation of glucocorticoid receptor 
in mouse keratinocytes increases susceptibility to skin tumorigenesis. J Invest Dermatol 
2013;133:2771–9. 
 
Leung WH, Vong QP, Lin W, Janke L, Chen T, Leung W. Modulation of NKG2D 
ligand expression and metastasis in tumors by spironolactone via RXRg activation. J 
Exp Med 2013;210:2675–92. 
 
Martinerie L, Munier M, Menuet DL, Meduri G, Viengchareun S, Lombès M. The 
mineralocorticoid signaling pathway throughout development: Expression, regulation 
and pathophysiological implications. Biochimie 2013;95:148–57. 
 
Maubec E, Laouénan C, Deschamps L, Nguyen VT, Scheer-Senyarich I, Wackenheim-
Jacobs AC et al. Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-
Induced Epidermal Atrophy in Human Skin. J Invest Dermatol 2015;135:1781–9. 
 
Messaoudi S, Milliez P, Samuel JL, Delcayre C. Cardiac aldosterone overexpression 
prevents harmful effects of diabetes in the mouse heart by preserving capillary density. 
FASEB J 2009;23:2176–85. 
 19
 
Mitts TF, Bunda S, Wang Y, Hinek A. Aldosterone and mineralocorticoid receptor 
antagonists modulate elastin and collagen deposition in human skin. J Invest Dermatol 
2010;130:2396–406. 
 
Nagase T, Akase T, Sanada H, Minematsu T, Ibuki A, Huang L et al. Aging-like skin 
changes in metabolic syndrome model mice are mediated by mineralocorticoid receptor 
signaling. Aging Cell 2013;12:50–7. 
 
Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling 
mechanisms in health and disease. J Allergy Clin Immunol 2013;132:1033–44. 
 
Oakley RH, Cidlowski JA. Glucocorticoid signaling in the heart: 
A cardiomyocyte perspective. J Steroid Biochem Mol Biol 2015;153:27–34. 
 
Odermatt A, Atanasov AG. Mineralocorticoid receptors: emerging complexity and 
functional diversity. Steroids 2009;74:163–71. 
 
Pastar I, Stojadinovic O, Yin NC, Ramirez H, Nusbaum AG, Sawaya A et al. 
Epithelialization in Wound Healing: A Comprehensive Review. Adv Wound Care (New 
Rochelle) 2014;3:445–64. 
 
Pérez P, Page A, Bravo A, del Río M, Gimenez-Conti I, Budunova I et al. Altered skin 
development and impaired proliferative and inflammatory responses in transgenic mice 
overexpressing the glucocorticoid receptor. FASEB J 2001;15:2030–36. 
 
Pérez P. Glucocorticoid receptors, epidermal homeostasis and hair follicle 
differentiation Dermato-Endocrinology 2011;3:1–9. 
 
Radoja N, Komine M, Jho SH, Blumenberg M, Tomic-Canic M. Novel mechanism of 
steroid action in skin through glucocorticoid receptor monomers. Mol Cell Biol 
2000;20:4328–39. 
 
Ramírez A, Page A, Gandarillas A Zanet J, Pibre S, Vidal M et al. A keratin K5Cre 
transgenic line appropriate for tissue–specific or generalized Cre–mediated 
recombination. Genesis 2004;39:52–7. 
 
Ronchetti S, Migliorati G, Riccardi C. GILZ as a Mediator of the Anti-Inflammatory 
Effects of Glucocorticoids. Front Endocrinol 2015;6:170.doi: 
10.3389/fendo.2015.00170. 
 
Sainte Marie Y, Toulon A, Paus R, Maubec E, Cherfa A, Grossin M et al. Targeted Skin 
Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, 
Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia. Am J Pathol 
2007;171:846–60. 
 
Sanchis A, Alba L, Latorre V, Sevilla LM, Pérez P. Keratinocyte-targeted 
overexpression of the glucocorticoid receptor delays cutaneous wound healing. PLoS 
One 7 2012;(1):e29701.  
 
 20
Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of 
glucocorticoids. Pharmacol Ther 2002;96:23–43. 
 
Sevilla LM, Latorre V, Sanchis A, Pérez P. Epidermal inactivation of the glucocorticoid 
receptor triggers skin barrier defects and cutaneous inflammation. J Invest Dermatol 
2013;33:361–70.  
 
Sevilla LM, Latorre V, Carceller E, Boix J, Vodak D, Mills IG et al. Glucocorticoid 
receptor and klf4 co-regulate anti-inflammatory genes in keratinocytes. Mol Cell 
Endocrinol 2015;412:281–9. 
 
Slominski AT, Manna PR, Tuckey RC. Cutaneous glucocorticosteroidogenesis: 
securing local homeostasis and the skin integrity. Exp Dermatol 2014;23:369–74. 
 
Stojadinovic O, Brem H, Vouthounis C, Lee B, Fallon J, Stallcup M et al. Molecular 
pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of 
epithelialization and wound healing. Am J Pathol 2005; 167:59–69. 
 
Torres J, Watt FM. Nanog maintains pluripotency of mouse embryonic stem cells by 
inhibiting NFkappaB and cooperating with Stat3. Nat Cell Biol 2008;10:194–201. 
 
Tiganescu A, Tahrani AA, Morgan SA, Otranto M, Desmoulière A, Abrahams L et al. 
11b-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and 
function defects. J Clin Invest 2013;123:3051–60. 
 
Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-
inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-
receptor-mediated transactivation. Endocrinology 2013;154:993–1007. 
 
Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès 
M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological 
biology. Nucl Recept Signal 2007;5:e012. doi: 10.1621/nrs.05012. 
 
Vukelic S, Stojadinovic O, Pastar I, Rabach M, Krzyzanowska A, Lebrun E et al. 
Cortisol synthesis in epidermis is induced by IL‐1 and tissue injury. J Biol Chem 
2011;286:10265–75. 
 
Youm JK, Park K, Uchida Y, Chan A, Mauro TM, Holleran WM et al. 
Local blockade of glucocorticoid activation reverses stress- and glucocorticoid-induced 
delays in cutaneous wound healing. Wound Repair Regen 2013;21:715–22. 
 
 21
FIGURE LEGENDS 
Figure 1. Inactivation of the Mineralocorticoid Receptor in mouse epidermis 
(MREKO) results in increased keratinocyte proliferation and differentiation. 
(a) Scheme depicting generation of MREKO (K5-cre//MRloxP/loxP) mice by intercrossing 
K5-Cre males that express the Cre recombinase under control of the keratin 5 (K5) 
promoter and MRloxP/loxP females that have the third exon of the MR gene flanked by 
loxP sequences. (b) Agarose gel showing specific bands from genotyping of MREKO, 
MRloxP/loxP, or MRloxP/+ mice. (c) qRT-PCR showing Nr3c2 (MR) mRNA levels in 
epidermal keratinocytes from MREKO and MRloxP/loxP (CO) littermates. Student’s t-test; 
***, p<0.001; n=at least 4 mice per genotype. (d) Immunostaining of MREKO and CO 
adult skin sections; LOR, loricrin; K6, keratin 6. Bar: 100 m. *, abnormal K6 staining; 
<, focal increases of LOR. (e) Quantification of epidermal thickness in MREKO (n=12) 
and CO (n=11) mice. Student’s t test; ***, p<0.001. (f) Percent BrdU-positive 
keratinocytes. Student’s t-test; *, p<0.05, n=5 per genotype. (g) Growth kinetics of 
MREKO and CO keratinocytes. Student’s t-test; **, p<0.01, n=4 per genotype and time 
point. (h-i) CO and MREKO keratinocytes treated with 1.2 mM calcium for 0 or 72h. 
Differentiation-associated morphological changes (h); asterisks, cornified envelopes. 
Bar: 50 μm. Gene expression assessed by qRT-PCR (i). Post hoc Tukey test *, #, 
p<0.05; ***, ###, p<0.001, n=3-5 per genotype and time point. Asterisks: significance 
between time points within each genotype; hashes: significance between genotypes at 
the same time point. c, e-g, i: Mean values ± SD are shown.  
 
Figure 2. Loss of MR causes increased epithelial damage after SDS treatment. 
(a) H&E staining and K6 immunostaining of CO and MREKO dorsal skin sections 
treated with vehicle (V) or 10% SDS; brackets, epidermal thickness; asterisks, 
hyperkeratosis. Bar: 100 m. (b, c) Quantification of epidermal thickness (b) and BrdU-
positive keratinocytes (c) in V and SDS-treated mice. (d-e) Representative immunoblots 
(upper) and quantitations (lower) for S100A9 (d), phospho(p)-STAT3 and STAT3 (e). 
Loading control: Actin. b-e: Mean values ± SD are shown. n= at least 4 mice per 
genotype and treatment. Post hoc Tukey test #, p<0.05; **, ##, p<0.01; ***, ###, 
p<0.001. Asterisks: significance between treatments within each genotype; hashes: 
significance between genotypes in the same treatment group. 
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Figure 3. MREKO mice and cultured keratinocytes show increased PMA-induced 
inflammation.  
(a-b) H&E-stained sections and ear thickness quantification of CO and MREKO mouse 
ears treated with vehicle (V, n=4 per genotype) or PMA (n=8 per genotype) for 48h; 
asterisks, inflammatory abscesses. Bar: 100 m. Post hoc Tukey test *, #, p<0.05; ###, 
p<0.001. (c-d) Gene expression of Tnfa, Il6 and Slpi assessed by qRT-PCR in V and 
PMA-treated (n=3 per genotype and treatment) CO and MREKO ears (c; Student’s t-test; 
*, p<0.05) or keratinocytes (d; Post hoc Tukey test #, p<0.05; ##, p<0.01; ***, ###, 
p<0.001; n=3 per genotype and treatment). Asterisks: significant differences upon 
treatment within each genotype; hashes: significant differences between genotypes in 
the same treatment group. (e) Activation of NF-B-luciferase reporter in CO, MREKO, 
and GREKO keratinocytes upon PMA treatment. Post hoc Tukey test ***, p<0.001; at 
least n=4 per genotype. b-e: Mean values ± SD are shown. 
 
 
Figure 4. Impaired cutaneous wound healing in MREKO mice due to defective 
keratinocyte migration. 
(a) Healing of full-thickness dorsal wounds was monitored for 7 d and percent area of 
wound closure quantitated. (b-c) Percentage of re-epithelialization (b) and percent 
BrdU-positive keratinocytes at d7 post-wounding. (d) H&E staining, K6 expression, and 
collagen deposition (MTC, Masson’s trichrome staining) in CO and MREKO wounds; 
arrows, original wound edges; <, collagen. Bar: 100 m. (e) Quantitation of relative 
collagen deposition. a-e: Mean values ± SD are shown; n= 7 CO and 9 MREKO mice. 
Student’s t test; *, p<0.05. (f-g) CO and MREKO keratinocyte monolayers were 
evaluated for wound closure at indicated times following scratching. Bar: 50 μm. Graph 
(g) shows the average of wound closure ± SD. Student’s t test; ***, p<0.001, n=8 per 
time-point and genotype.  
 
 
Figure 5. Epidermal MR inactivation partially protects against Dex-induced skin 
atrophy. 
(a-b) Dorsal CO and  MREKO skin was treated with vehicle (V) or Dex for 7 d. H&E 
staining and K5 expression (a) in skin sections; arrows, epidermal thinning. Collagen 
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deposition (b) evaluated by Masson’s trichrome staining. Bar: 100 m. (c) Percent 
BrdU-positive keratinocytes after 48h of Dex treatment. (d-e) qRT-PCR assessing 
Cyclin D1 (Ccnd1, d) and Collagen 1a1 (Col1a1, e) expression in CO and MREKO skin 
treated with V or Dex (48h for Ccnd1 and 7 d for Col1a1). c-e, Mean values ± SD are 
shown; n=3 per genotype and treatment. Post hoc Tukey test *, #, p<0.05; **, p<0.01; 
***, ###, p<0.001. Asterisks: significant differences upon treatment within each 
genotype; hashes: significant differences between genotypes in the same treatment 
group.  
 
Figure 6. Loss of MR in keratinocytes decreases transcriptional up-regulation of 
GC-target genes. 
(a) Fold-activation of GRE-luciferase (GRE-luc) in Dex- relative to vehicle-treated CO 
and MREKO keratinocytes after transfection with empty vector (EV) or HA-MR. n=9 per 
genotype and treatment. (b) Immunoblotting showing HA-MR and GR in untreated 
transfected cells; loading control: Actin. (c) Immunofluorescence of HA-MR transfected 
CO keratinocytes. HA, green; GR, red; overlay (DAPI, blue). Bar: 20 m (d) 
Immunoblot showing GR and p-GR in vehicle- and Dex-treated CO and MREKO 
keratinocytes; loading control: Tubulin (TUB). (e) qRT-PCR showing Gilz expression 
in CO, MREKO and GREKO keratinocytes treated with vehicle or Dex. n=3 per genotype 
and treatment. (f) ChIP qPCR assessing GR recruitment to Gilz regulatory sequences in 
vehicle- or Dex-treated CO and MREKO keratinocytes. n=4 per genotype and treatment. 
(g) Activation of GRE-luc reporter in GREKO cells transfected with EV, MR, GR, or 
both in response to Dex. (h) Immunoblot shows expression of HA-MR and GR in 
untreated transfected cells; loading control: Actin. a, e-g: Mean values ± SD are shown. 
Post hoc Tukey test *, #, p<0.05; **, ##, p<0.01; ***, ###, p<0.001 Asterisks: 
significant differences upon treatment within each genotype; hashes: significant 
differences between genotypes in the same treatment group. 
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Fig S1. Nr3c1 expression does not change in MREKO relative to CO mouse skin under different
experimental conditions. Relative Nr3c1 levels determined by qRT-PCR in CO and MREKO dorsal skin
subjected to different treatments prior to collection. (a) Daily application of vehicle (V) or SDS for 5 d; n=3
per genotype and treatment. A single treatment with V or PMA followed by 48h; n=4 CO, n=5 MREKO per
genotype and treatment. (c) Treatment with V or Dex every 48h for 7 d; n=3 per genotype and treatment.
Post hoc Tukey test * p<0.05; ***p<0.001 respective to V treatment of same genotype.
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Fig S2. Collagen deposition does not change in MREKO
relative to CO mouse skin. Relative collagen deposition
represented as the integrated density was measured in
Masson’s Trichrome stained sections of CO and MREKO mice
(n=4 per genotype).
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Fig. S3. Treatment of CO keratinocytes with the MR antagonist
Eplenerone delays cell migration. CO keratinocyte monolayers were treated
with vehicle (V) or eplerenone (E, 10 µM) 24h before scratching; after wound
scratch, additional treatments were performed with V or eplerenone for the
duration of the experiment. Wound closure was evaluated at indicated times.
Graph shows the average of wound closure ± SD. Student’s t test; *, p<0.05,
n=at least 8 per time point and treatment.
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Fig. S4. Treatment of CO keratinocytes with the MR antagonist
Eplenerone diminishes Dex induction of GRE-luciferase reporter.
Activation of GRE-luciferase (GRE-luc) in CO cells treated as indicated.
Cells were pre-treated with vehicle or eplenerone (Eple, 10 µM) 16h
before further incubation with vehicle (V) or Dex (100 nM) for 5h. Post
hoc Tukey test ***p<0.001 relative to V treatment; ### p<0.001 among
groups indicated by bracket; n=4 per treatment group.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1. Primer sequences for genotyping, RT-QPCR, and ChIP 
Genotyping
Gene  Primer name  Sequence  Band size MRwt/wt  Band size MRflox/flox  Band size MRKO/KO 
Nr3c2  MR_F  CTGGAGATCTGAACTCCAGGCT  285bp (primers F‐RA)  335bp (primers F‐RA)  390bp (F‐RB) 
Nr3c2  MR_RA  TAGAAACACTTCGTAAAGTAGAGCT 
Nr3c2  MR_RB  CCTAGAGTTCCTGAGCTGCTGA 
RT qPCR       
Gene symbol  Forward sequence  Reverse sequence  product bp 
Ccnd1  CATCAAGTGTGACCCGGACTG  CCTCCTCCTCAGTGGCCTTG  116 
Col1a1  CTAAGGGTACCGCTGGAGAAC  GGGACCTTGTTCACCTCTCTC  155 
Defb1  CCTCATCTGTCAGCCCAACT   GTGAGAATGCCAACACCTGG   148 
Hprt1  TCAGTCAACGGGGGACATAAA  GGGGCTGTACTGCTTAACCAG  142 
Il6  GATGCTACCAAACTGGATATAATC   GGTCCTTAGCCACTCCTTCTGTG   269 
Nr3c1  TGCTATGCTTTGCTCCTGATCTG  TGTCAGTTGATAAAACCGCTGCC  299 
Nr3c2  GTGGACAGTCCTTTCACTACCG  TGACACCCAGAAGCCTCATCTC  286 
Slpi  TGGCACCCTGGACTGTGGAAGG  CCCGTCCCTCTGGCAGACAT  278 
Sprr2d  TGGTACTCAAGGCCGAGA  TTTGTCCTGATGACTGCTGAAGAC  336 
Tnfa  CCCTCACACTCAGATCATCTTCT  GCTACGACGTGGGCTACAG  61 
Tsc22d3/Gilz  CTGTTGGCCTCGACTGCTG  GCCGAAAGTTGCTCACGAAG  111 
ChIP qPCR         
Gene symbol  Coordinates (Genome build mm9)  Forward sequence  Reverse sequence  product bp 
Tsc22d3/Gilz  chrX:137063820‐137063910  GGAGGGAATGCAACTGGGAG  CCCCTCCCTTGAATGCTGAA  91 
SUPPLEMENTARY INFORMATION 
SUPPLEMENTARY METHODS 
Quantitative analyses of histological samples 
To assess epidermal thickness, ear edema, and collagen deposition, images of H&E 
stained skin sections or Masson’s Trichrome (Sigma) stained-sections were used 
(IMAGE J software, Rasband, W.S., ImageJ, U. S. National Institutes of Health, 
Bethesda, Maryland). At least five photomicrographs were taken of each section and at 
least five measurements were taken from each photomicrograph, following a method of 
semi-randomization, which excluded altered zones. A Leica DM1000 microscope, a 
Leica EC3 camera and Leica LAS EZ software (Leica Microsystems, Wetzlar, 
Germany) were used. To quantitate collagen deposition, the integrated density of 
collagen fibers (product of area occupied by collagen and mean collagen intensity) was 
determined. In skin wounds, images were taken from the newly formed dermis under 
the original wound. 
Generation of cell lines 
CO and GREKO cell lines were previously described (Sevilla et al., 2013). 
Adult MREKO keratinocyte cell lines were generated from 8-wk-old female 
mouse dorsal skin, following established protocols (Romero et al., 1999; Reichelt and 
Haase, 2010). Briefly, keratinocytes were isolated following overnight incubation of 
skin with 0.25% trypsin-PBS at 4oC and cultured on mitomycin C treated J2-3T3 
feeders in type I collagen-coated flasks in DMEM-Ham’s F12 (3:1) medium (Thermo 
Fisher; Biowest, Nuaillé, France) supplemented with 1.8 × 10−4 mol/l adenine (Sigma), 
0.35 mM calcium, 7.5% FBS Gold (Biowest), 100 U/ml penicillin/100 μg/ml 
streptomycin (Biowest), 2 mM glutamine (Biowest), 0.25 μg/ml amphotericin B 
(Biowest), 5 μg/ml insulin (Sigma), 10−10M cholera toxin (Sigma) and 10 ng/ml EGF 
(Peprotech, Rocky Hill, NJ). Following approximately 7-10 passages, spontaneously 
immortalized lines arose. Immortal cell lines were maintained using the conditions 
described above. 
 
Transfection and Luciferase assays 
Keratinocytes at 70-90% confluence were transfected with combinations of the 
following plasmids: pCDNA4 (Thermo Fisher), pCDNA4-HA-MR (Aguilar-Sánchez et 
al., 2012), pGRE2EIB-Luciferase (Allgood et al. 1993), pGL3-NF-5x-Luciferase 
(Torres and Watt, 2008), and the internal control pRL-SV40 Renilla (Promega) using 
Lipofectamine 2000 Reagent (Thermo Fisher). 24h after transfection, cells were treated 
with 100 nM Dex for 5 h or 100 nM PMA for 6h. Where indicated, cells were pre-
treated 16 h with eplerenone (10 µM). Luciferase activity was measured using the dual 
luciferase assay system (Promega) and a Wallac Victor2 1420 multilabel counter. 
Firefly-luciferase levels were normalized to those of Renilla luciferase. 
 
Immunofluorescence 
For immunofluorescence, cells were grown on collagen I-coated coverslips, and 
analyzed using a confocal microscope (Espectral Leica TCS SP8; Latorre et al., 2013). 
Images were processed using IMAGE J software and are presented as maximum 
projections of Z stack series. 
 
Growth curve 
500 CO and MREKO keratinocytes were plated per well of a 96-well plate (n=4 per 
genotype and time point). On day 0, 3, 5 and 7, 20 µl per well of CellTiter 96® 
AQueous One Solution Cell Proliferation Assay Reagent (Promega Corp., Madison, 
WI) was added and incubated for 3h at 37°C. Absorbance was measured at 490nm using 
a Wallac Victor2 1420 multilabel counter.  
 
Wound scratch assays 
Confluent cells were treated with mitomycin C (Sigma, 4g/ml, 1h) before scratching 
cell monolayers with sterile white pipette tips. Following wounding, the percentage of 
cell migration was determined in photomicrographs taken at each time point (Sanchis et 
al., 2012). Results are average of n=8-9 biological replicates per genotype or treatment. 
Eight images were taken along each wound scratch per time point for subsequent 
analysis (Adobe Acrobat 8 Professional). 
To evaluate keratinocyte migration in response to eplerenone (10 µM), cells 
were preincubated 24 h before scratching; then, additional treatments were performed 
with vehicle or eplerenone for the duration of the experiment. 
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